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Introduction
The Bcl-2 family of proteins plays a major role in regulating 
apoptosis (Adams and Cory, 2007). Mammalian antiapoptotic 
members include Bcl-2, Bcl-xL, or Mcl-1 and display sequence 
conservation throughout four Bcl-2 homology domains (BH1–4). 
They oppose the multidomain proapoptotic proteins such as Bax 
and Bak, which share BH1, -2, and -3 in common with Bcl-2, 
and the BH3-only proteins (e.g., Bid, Bim, Puma [p53 up-regulated 
modulator of apoptosis], Bad, and Noxa; Puthalakath and Strasser, 
2002). The resistance of murine cells lacking both Bax and Bak 
to cell death induction by multiple stimuli, including to BH3-
only proteins, implies that antiapoptotic Bcl-2 homologues favor 
survival by antagonizing the recruitment by death signals 
and/or the activity of Bax/Bak (Adams and Cory, 2007). This 
prosurvival activity relies in great part on the ability of Bcl-2 
homologues to engage the BH3 domains of Bax, Bak, or BH3-only 
proteins (Petros et al., 2004). Thus, the mechanisms through 
which Bcl-2 homologues allow survival is linked to those 
through which BH3-only proteins induce apoptosis upstream of 
Bax/Bak.
One model for BH3-induced apoptosis proposes that re-
leasing Bax/Bak from survival Bcl-2 homologues is sufficient 
to promote cell death (Willis et al., 2005, 2007; Adams and 
Cory, 2007). This is achieved when the BH3-binding sites of 
diverse Bcl-2 homologues, which slightly differ in structure 
(Petros et al., 2004; Chen et al., 2005; Certo et al., 2006), are 
occupied by promiscuous BH3-only proteins (such as Bid, Bim, 
or Puma) or by the combination of more selective ones (such as 
Bad or Noxa). This model does not fully integrate the notion 
that native Bax is essentially inert and that substantial confor-
mational changes are required for this protein to kill cells (Lalier 
et al., 2007a): induction of Bax-dependent apoptosis must rely 
on  some  Bax-activating  signals. Another  model  for  BH3- 
induced apoptosis proposes that such signals are provided by 
some BH3-only proteins: death agonists such as Bid, Bim, and 
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t  is  still  unclear  whether  the  BH3-only  protein  Puma 
(p53 up-regulated modulator of apoptosis) can prime 
cells to death and render antiapoptotic BH3-binding 
Bcl-2 homologues necessary for survival through its ability 
to directly interact with proapoptotic Bax and activate it. 
In this study, we provide further evidence, using cell-free 
assays, that the BH3 domain of Puma binds Bax at an   
activation site that comprises the first helix of Bax. We also 
show that, in yeast, Puma interacts with Bax and triggers 
its killing activity when Bcl-2 homologues are absent but 
not when Bcl-xL is expressed. Finally, endogenous Puma   
is involved in the apoptotic response of human colorectal 
cancer cells to the Bcl-2/Bcl-xL inhibitor ABT-737, even in 
conditions where the expression of Mcl-1 is down-regulated. 
Thus, Puma is competent to trigger Bax activity by itself, 
thereby  promoting  cellular  dependence  on  prosurvival 
Bcl-2 family members.
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In two-hybrid assays, the interaction between Puma (or its 
sole BH3 domain) and Bax (or its first  helix) is prevented by 
the alteration within Bax of an aspartate at position 33 (i.e., in 
the C-terminal end of Bax H1) into an Ala (Cartron et al., 2004a). 
To confirm a role for this residue in the interaction of cellular 
Bax with Puma BH3, we used cell lysates made from originally 
Bax-deficient GBM (BdGBM) cells that were engineered to ex-
press wild-type Bax, the BaxD33A variant, or the BH3-mutated 
BaxK64A variant as a control (Cartron et al., 2004a). Wild-type 
Bax and BaxK64A but not BaxD33A were pulled down by 
Biot-Puma
BH3 despite the comparable expression of each pro-
tein in the lysates used (Fig. 1 A). Thus, D33 is involved in the 
interaction of Puma BH3 with Bax. Incidentally, this also demon-
strates the specificity of the interaction evaluated by this pull-
down assay.
In an independent approach to map regions within the 
N-terminal end of Bax involved in its interaction with Puma 
BH3, we performed a linear peptide scan derived from epitope 
mapping (Brix et al., 1999). This approach helped to define the 
molecular motifs involved in the interaction between Bax and 
its mitochondrial receptor, TOM22 (Bellot et al., 2007). It was 
based on the use of nitrocellulose membranes on which 12-mer 
peptides, overlapping by 10 residues and covering the sequence 
of Bax comprised between residues 1–106, are covalently 
bound. Membranes were incubated with Biot-Puma
BH3, and the 
presence of peptides bound to each Bax peptide was revealed 
using avidin-coupled peroxidase (Fig. 1 B). Peptides compris-
ing residues 25–36, 27–38, and 29–40, which are located in the 
C-terminal end of Bax H1, were strongly labeled by Biot-
Puma
BH3. Another region, which encompasses residues 89–100 
and map to Bax H4, showed some, albeit weaker, interaction 
with Biot-Puma
BH3, but most other peptides exhibited no de-
tectable interaction. Collectively, these data reveal a prefer-
ential interaction between Puma BH3 and the C-terminal end of 
Bax H1.
The aforementioned Puma BH3–Bax H1 interaction re-
calls our previous study showing that a peptide encompassing 
the first helix of Bax (H1
Bax) could prevent the interaction be-
tween Puma and in vitro–translated Bax (Cartron et al., 2004a). 
Likewise, an excess of this 20-mer peptide but not that of a 
mutant peptide bearing the D33A mutation prevented the inter-
action between Biot-Puma
BH3 and cellular Bax in pull-down 
assays (Fig. S1 B). We inferred from Pepscan analysis that con-
tiguous residues at the C-terminal end of Bax H1 might suffice 
to interact with the Puma BH3 domain and that a shorter peptide 
encompassing these residues might also prevent the interaction 
between Puma BH3 and cellular Bax. Thus, we analyzed the 
effects of a 7-mer peptide (H1 C terminus [H1-Cter]; residues 
31–37) in pull-down assays. 10 µM of this peptide inhibited the 
interaction between Biot-Puma
BH3 and Bax from BeGBM lysates 
(Fig. 1 C). Of note, it also inhibited the ability of Biot-Puma
BH3 
to interact with Bax present in the cytosolic fraction of immor-
talized rat fibroblasts, whereas a mutant 7-mer peptide carrying 
the D33A mutation or other 7-mer peptides comprising adjacent 
residues 25–31 or residues 92–98 did not (unpublished data).
We used H1-Cter as a tool to investigate whether the inter-
action of Puma BH3 with Bax accounts for the ability of the 
possibly Puma harbor a BH3 domain that can promote ligand-
induced activation of Bax, and other survival antagonist BH3-
only proteins (Bad and Noxa) allow this process to occur by 
preventing Bcl-2 homologues to sequester death agonists (Wang 
et al., 1996; Kuwana et al., 2002, 2005; Letai, et al., 2002; 
Cartron et al., 2004a). The validity of this model has also been 
discussed, as it has been difficult to demonstrate the interaction 
between endogenous purported death agonist BH3-only pro-
teins and Bax during the course of cell death.
Whether certain BH3-only proteins are factors that, inde-
pendently from antiapoptotic Bcl-2 homologues, prime cells to 
Bax-dependent cell death is a key question regarding the biol-
ogy of human cancer cells because (a) the apoptotic response of 
these cells, including to BH3-only proteins, generally depends 
in great part on Bax and much less on Bak to be efficient and 
(b) Bcl-2 homologues are highly expressed in these cells and con-
tribute to their aberrant survival (Letai, 2008). These data, to-
gether with the recent development of a small molecule inhibitor 
of the BH3-binding activity of Bcl-xL and Bcl-2 (ABT-737; 
Oltersdorf et al., 2005), make timely the identification of pro-
teins that contribute to induction of cell death induced by inhibi-
tion of Bcl-2 homologues.
Puma is an essential mediator of p53-dependent and   
-independent apoptosis in vivo (Jeffers et al., 2003; Villunger 
et al., 2003). We showed that Puma, and its BH3 domain in 
particular, might promote ligand-induced activation of Bax 
(Cartron et al., 2004a). This has been debated since then (Certo 
et al., 2006; Willis et al., 2007), even though recent evidence has 
suggested that Puma is a potent activator of cellular Bax and 
might function downstream of survival antagonist BH3-only 
proteins Bad and Noxa (Kim et al., 2006). In this study, we have 
analyzed the nature of the interaction between the BH3 domain 
of Puma and Bax, and we have investigated whether Puma ex-
erts a Bax-activating function independently from Bcl-2 homo-
logues and whether, consistently, Puma plays an active role 
when death is triggered in human cancer cells by inhibition of 
these survival proteins.
Results
The BH3 domain of Puma physically and 
functionally interacts with Bax
We previously identified Puma as a binding partner of the first   
 helix of Bax (Bax H1; residues 20–37) from a bacterial two-
hybrid screen, and subsequent two-hybrid assays showed that 
the sole BH3 region of Puma (residues 127–150) interacts with 
Bax H1 and full-length Bax (Cartron et al., 2004a). To investi-
gate whether Puma BH3 can interact with cellular Bax, we used 
a biotinylated 24-mer peptide (Biot-Puma
BH3) that encompasses 
this domain. Pull-down assays after incubation of 1 µM Biot-
Puma
BH3 with 500-µg lysates from glioblastoma cells expressing 
endogenous Bax (Bax-expressing glioblastoma multiforme 
[GBM; BeGBM]) showed that this peptide bound to endogenous 
Bcl-xL and also to Bax. Both interactions were inhibited by an 
excess of nonbiotinylated peptide (Fig. S1 A). In the absence of 
competing peptide, 2% of the initial Bax and 10% of initial 
Bcl-xL were pulled down by Biot-Puma
BH3 (unpublished data).281 BAX ACTIVATION BY PUMA • Gallenne et al.
cell-free systems (Kuwana et al., 2005; Certo et al., 2006) 
remains to be elucidated. In an integrated approach to measure 
Bax apoptogenicity, we also measured induction of cell death 
by the microinjection of recombinant Bax, which had been pre-
incubated with various peptides. Experiments were performed 
in human glioblastoma cells in which Bax expression was se-
lectively knocked down by RNA interference (GBM shBax; 
Manero et al., 2006) to avoid interference of endogenous Bax. 
Consistent with previous studies (Cartron et al., 2003, 2004a), 
100 nM Puma
BH3 only induced weak, background cell death 6 h 
after its microinjection in GBM shBax, whereas it induced sig-
nificant cell death amounts in control cells (GBM scramble 
former to promote the activity of the latter. We have shown that 
Puma
BH3 can induce an apoptotic-like change of conformation 
in in vitro–translated Bax and trigger its mitochondrial activity, 
whereas nonactivator peptides such as Bad
BH3 do not (Cartron 
et al., 2004a). In dose-response experiments, we detected no 
differences between the efficiency of Puma
BH3 and that of other 
purported activator BH3 peptides (such as Bid
BH3) to impact on 
Bax conformation and activity (Fig. S1 C). H1-Cter inhibited, 
in a dose-dependent manner, this cell-free effect of Puma
BH3 on 
Bax, indicating that it relies on a physical interaction between 
the two molecules (Fig. S1 D). The reason why an impact of 
Puma
BH3 on Bax activity has been difficult to detect in other 
Figure 1.  Role of the C-terminal end of Bax H1 in the interaction of Bax with the BH3 domain of Puma. (A) Interaction of cellular Bax with a Puma BH3 
peptide. Lysates from BdGBM(Bax-), BdGBM(BaxD33A), and BdGBM(BaxK64A) cells expressing comparable amounts of Bax were used. Bax molecules 
pulled down from these lysates by biotinylated Puma
BH3 were evaluated by Western blotting. (bottom) In each independent experiment, the amount of 
pulled down Bax was quantitated by densitometry and normalized to the maximum intensity. (B) Pepscan analysis. Interaction of biotinylated Puma
BH3 with 
nitrocellulose membranes, on which were spotted 48 12-mer peptides covering the indicated sequence of Bax, was analyzed as described in Materials and 
methods. The top panel shows one representative autoradiogram. Peptides range from A1, which is the 12-mer peptide encompassing residues 1–12, to 
B24, which is the 12-mer peptide encompassing residues 95–106. In the bottom panel, the mean binding intensities (which were evaluated by densitometry 
and normalized to the maximum binding intensity) for three independent experiments using three different membranes are represented for each peptide. 
The positions of helices 1–4 (as defined in Suzuki et al. [2000]) are shown for illustration. (C) Interaction of cellular Bax with Puma
BH3 in the presence 
of Bax H1-Cter peptide. Pull-down experiments were performed as in A, using lysates from BeGBM cells. Where indicated, 10 µM Bax H1-Cter was 
added to lysates before pull-down. (A and C) Data are mean ± SEM of three independent experiments. P-values were assessed using a Student’s t test. 
A.U., arbitrary unit; WB, Western blot; WT, wild type.JCB • VOLUME 185 • NUMBER 2 • 2009   282
Puma cooperates with Bax to  
promote yeast cell death in a  
Bcl-xL–sensitive manner
To investigate whether Puma and Bax can physically interact 
and functionally cooperate to promote cell death in the absence 
of Bcl-2 homologues, we analyzed the effects of their expres-
sion in yeast, which express no recognized Bcl-2 family pro-
teins. When expressed in yeast, full-length untagged human 
Bax remains cytosolic and induces neither cytochrome c release 
nor cell death (Priault et al., 2003; Arokium et al., 2004). 
Nevertheless, conformational changes of the protein caused by 
substitution of critical residues can promote mitochondrial trans-
location and the subsequent release of cytochrome c (Arokium 
et al., 2004). We generated yeast strains that express galactose-
inducible Bax, Puma, or both. Although the induction of Puma 
only (not depicted) or that of wild-type Bax only (Fig. 3 A) had 
no detectable effect on yeast viability, the coexpression of Bax 
and Puma induced yeast cell death (Fig. 3 A) and cytochrome c 
release (Fig. 3 C). Cell death induced by Puma and Bax, as pre-
viously reported for that induced by active substituted Bax mu-
tants (Arokium et al., 2004), was prevented by the expression of 
Bcl-xL (Fig. 3 A).
To evaluate whether the functional cooperation between 
Puma and Bax involved Bax H1, we then used yeast strains 
expressing galactose-inducible BaxD33A. This mutant promoted 
some cytochrome c release and cell death by itself (Fig. 3,   
B and C), most likely owing to a partial unfolding induced by the 
mutation (Cartron et al., 2005; Arokium et al., 2007). Neverthe-
less, the deleterious effects of BaxD33A in yeast cells were not 
stimulated by the coexpression of Puma, even at early time 
points after induction (Fig. 3, B and C).
Coimmunoprecipitation experiments were performed to 
investigate whether the functional cooperation between Puma 
and Bax coincided with a physical interaction between these 
two proteins. Wild-type Bax and Puma interacted with each 
[scr]; Fig. 2). Although microinjection of 100 nM recombinant 
Bax by itself was mostly inefficient at inducing cell death in 
GBM shBax cells, microinjection of 100 nM Bax that had been 
preincubated with 100 nM Puma
BH3 (for 60 min at 37°C) did 
promote significant cell death (Fig. 2). The ability to trigger Bax 
induction of cell death was also found for Bid
BH3, but it was not 
observed for Bad
BH3 (Fig. S1 E), indicating that this short-term 
system assays the apoptogenicity of the injectate at the time of 
microinjection. H1-Cter diminished the ability of Puma
BH3 to 
promote cell death in Bax-expressing, GBM scr cells (Fig. 2). 
Moreover, when this peptide was added to Puma
BH3 before in-
cubation with recombinant Bax and microinjection in GBM 
shBax cells, no significant cell death could be detected, indicating 
that enhancement of Bax activity by Puma
BH3 was inhibited by 
H1-Cter (Fig. 2). Importantly, when H1-Cter was added to 
the microinjection preparation after Bax had been incubated 
with Puma
BH3, the resulting mixture proved as efficient at induc-
ing cell death in GBM shBax cells as the mixture without H1-
Cter (Fig. 2). Thus, in this system, H1-Cter exerts an inhibitory 
effect during the incubation of Puma
BH3 with Bax, but it has no 
effect on the cell response to the mixture. In contrast, recombi-
nant Bcl-xL prevented Puma
BH3 activation of Bax when added 
not only before but also after incubation of the peptide with 
Bax, supporting the idea that Bcl-xL can exert control over both 
ligand-induced Bax activation and Bax activity (Fig. S1 F). 
Importantly, microinjected H1-Cter also prevented induction 
of cell death by overexpression of Puma in GBM cells, and Puma-
dependent induction of cell death by Adriamycin in HCT116 
cells (Fig. S2). These observations, together with our previous 
study showing that ectopic wild-type Bax- or BaxK64A but 
not ectopic BaxD33A restores the sensitivity of Bax-deficient 
glioblastoma cells to Puma and Puma
BH3 (Cartron et al., 2002), 
are in strong agreement with the notion that the interaction of 
Puma BH3 with Bax H1 enhances Bax activity and promotes 
cell death.
Figure  2.  Functional  cooperation  between 
Puma
BH3 and Bax. The indicated GBM cells were 
microinjected  with  combinations  of  100  nM   
Puma
BH3, 1 µM H1-Cter, and/or 100 nM re-
combinant  Bax  together  with  a  fluorescent   
microinjection marker (0.5% FITC–dextran 40S).   
Where  indicated,  H1-Cter  was  incubated 
with Puma
BH3 before incubation with Bax or 
after  Puma
BH3  was  incubated  with  Bax.  The 
percentage  of  properly  microinjected  (i.e., 
fluorescent)  cells  exhibiting  morphological 
features of cell death was assayed 6 h after   
microinjection. Data are mean ± SEM of at 
least three independent experiments. P-values 
were assessed using a Student’s t test.283 BAX ACTIVATION BY PUMA • Gallenne et al.
tested, further underscoring the importance of Bax in the apop-
totic response of these human cancer cells. Puma
/ cells ex-
hibited some cell death response at high concentrations of 
ABT-737, but it was much lower than that induced in control 
cells (Fig. 4 B). A closer examination of the death pathways in-
volved was performed by immunocytochemical analysis of 
cytochrome c localization and caspase 3 activation (using a 
conformation-specific antibody). The percentage of cells ex-
hibiting cytochrome c release and caspase 3 activation after 
ABT-737 treatment was much lower in Puma
/ cells than in 
control cells (Fig. 4 C). ABT-737 at 10 µM had no detectable effect 
on cytochrome c release or caspase 3 activation in Bax
/ cells. 
Thus, Puma is implicated in induction of cytochrome c re-
lease, caspase 3 activation, and apoptotic cell death by ABT-737. 
As  we  could  not  detect  any  increase  in  Puma  expression 
upon ABT-737 treatment (Fig. S3 A), we infer that endogenous 
levels of Puma are sufficient to mediate these effects. We 
checked that the knockdown of Puma expression in control 
HCT116 cells by RNA interference conferred resistance to 
ABT-737–induced caspase 3 activation and cell death (Fig. S3, 
B and C). Notably, the resistance of Puma knockdown cells 
was not as marked as that of Puma knockout cells, suggesting 
that the remaining levels of Puma in the knockdown cells could 
still mediate ABT-737–induced cell death. Microinjection of 
H1-Cter peptide into control HCT116 cells significantly in-
hibited ABT-737 induction of cell death (Fig. S3 D), further 
supporting the notion that Puma is involved in this process. 
other in a yeast context, whereas BaxD33A and Puma could not 
(Fig. 3 D). Moreover, Bcl-xL expression inhibited this inter-
action (Fig. 3 E). Thus, Puma and Bax physically interact and 
functionally cooperate by a Bax H1–dependent, Bcl-xL–sensitive 
process, even in a cellular context that lacks known equivalents 
of the mammalian apoptotic machinery.
Puma plays a role in Bax-dependant 
apoptosis induced by inhibition or  
down-regulation of Bcl-xL
We investigated whether the aforementioned activation of Bax 
by Puma could take place in mammalian cells. As this activation 
involves the BH3 domain of Puma and is prevented by Bcl-xL, 
we reasoned that its occurrence in mammalian cells would de-
fine Puma as an actor of cell death that ensues when Bcl-2 
homologues are inhibited. Thus, we analyzed whether Puma plays 
a role when cell death is induced by ABT-737, a potent inhibitor 
of the BH3-binding activity of Bcl-xL and Bcl-2 (Oltersdorf 
et al., 2005), using the human colorectal cancer cell line HCT116 
p21
/ and its isogenic counterparts in which genetic ablation 
of Puma or Bax was performed (p21
/Puma
/ and p21
/ 
Bax
/; Fig. 4 A).
We analyzed the response of control, Puma
/, and Bax
/ 
cells to 24-h treatment with increasing concentrations (1–10 µM) 
of ABT-737. As shown in Fig. 4 B, ABT-737 induced dose-
dependent cell death in control cells. Bax
/ cells were com-
pletely resistant to this short-term treatment at all concentrations 
Figure 3.  Interaction of Bax and Puma in yeast. (A) Yeast cell survival after Bax, Puma, and Bcl-xL coexpression. Induction of Bax, Puma, and/or Bcl-xL 
in the corresponding yeast cells and survival assays at the indicated time after induction were performed as described in Materials and methods. (B) Yeast 
cell survival after BaxD33A and Puma coexpression. The experiment was performed as in A. (C) Cytochrome c release after wild-type Bax, BaxD33A, and 
Puma coexpression. Cytochrome (Cyt.) content in mitochondria isolated from the indicated yeast cells 14 h after induction was measured as described in 
Materials and methods. (D) Puma interaction with wild-type Bax and BaxD33A in yeast. Extracts from cells coexpressing Bax (or BaxD33A) and Puma were 
immunoprecipitated with anti-Bax antibody, and immunoprecipitates were analyzed for the presence of Bax and Puma by Western blotting. (E) Effect of 
Bcl-xL on Puma–Bax interactions in yeast. Extracts from cells coexpressing Bax and Puma, BaxD33A and Puma, or Bax, Puma, and Bcl-xL were treated as 
in D. (A–C) Data are mean ± SEM of three independent experiments.JCB • VOLUME 185 • NUMBER 2 • 2009   284
cannot be ruled out when high concentrations are used for long 
periods of treatment.
The aforementioned experiments suggest that some sur-
vival proteins targeted by ABT-737 constitutively maintain survival 
of the cells used in this study by counteracting Puma. We ana-
lyzed the acute effects of RNA interference–mediated Bcl-xL 
knockdown in control, Puma
/, and Bax
/ cells. We used 
a recombinant lentivirus that expresses GFP together with a 
short hairpin RNA targeting Bcl-xL (shBcl-xL) and infection 
conditions that lead to a profound loss of Bcl-xL expression 
(Fig. 5 A). Under these conditions, Bcl-xL knockdown induced 
the appearance of a significant number of cells with active cas-
pase 3 2 d after infection and massive cell death 3 d after infection 
in control cells, whereas infection with a control (scr) lentivirus 
had no effect (Fig. 5, B and C). As shown in Fig. 5 (B and C), 
RNA interference experiments and microinjection assays using 
H1-Cter also showed that endogenous Puma contributes   
to the apoptotic response of primary GBM cells to ABT-737 
(Fig. S3, E–G).
To analyze whether Puma was involved in long-term ef-
fects of ABT-737 on cell growth, control, Puma
/, and Bax
/ 
HCT116 cells were seeded at a low density and treated for 2 wk 
with 1–10 µM ABT-737 before visualization of viable clones. 
ABT-737 significantly affected the clonogenicity of control cells 
at all concentrations tested (Fig. 4 D). Puma
/ cells were strik-
ingly more resistant to these long-term effects, as only 10 µM 
ABT-737 had a major effect on their growth. Because the growth 
of Bax
/ cells was also affected at this concentration, the impli-
cation of Bax-independent mechanisms, of nonapoptotic growth 
inhibitory mechanisms, and/or that of off-target effects of ABT-737 
Figure 4.  Role of endogenous Puma in the biological activity of ABT-737. (A) Expression of Bcl-2 family members in HCT116-derived cell lines. Expression 
of 50 µg Puma, Bax, and Bcl-xL in lysates from the indicated cells was analyzed by Western blotting. WB, Western blot. (B) Induction of cell death by 
ABT-737 in human colorectal cancer cells. The indicated cells were incubated with the indicated concentration of ABT-737 for 24 h, and induction of cell 
death was assayed by a trypan blue–staining procedure. Data are mean ± SEM of four independent experiments. (C) Induction of apoptosis by ABT-737 
in human colorectal cancer cells. The indicated cells were incubated with the indicated concentration of ABT-737 for 24 h before immunocytochemical 
analysis of the percentage of cells exhibiting cytochrome c release and caspase 3 activation. Data are mean ± SEM of three independent experiments. 
(D) Long-term effects of ABT-737 on human colorectal cells. The indicated cells were treated for 2 wk with the indicated concentration of ABT-737 before 
analysis of viable clones by crystal violet staining. Data are mean ± SEM of at least three independent experiments and are expressed as a percentage 
of the number of colonies formed in untreated dishes. One experiment representative of three independent ones is shown in the top panel. (B–D) P-values 
were assessed using a Student’s t test.285 BAX ACTIVATION BY PUMA • Gallenne et al.
cell death in great part in these cells by antagonizing Puma. 
It implies that Puma exerts proapoptotic activity that is efficient 
in the absence of Bcl-xL and Mcl-1 and that is restrained by 
these proteins.
Puma
/ and Bax
/ cells were refractory to caspase 3 activa-
tion  and  cell  death  induced  by  lentivirus-mediated  down-
regulation of Bcl-xL. Of note, a recombinant lentivirus targeting 
Bcl-2 had a strikingly weaker effect on cell viability than the 
shBcl-xL lentivirus, but its feeble effect was also Puma depen-
dent (unpublished data). Interestingly, Fig. 5 A suggests that 
cell death induced by Bcl-xL knockdown in control cells may 
be slowed down by the unexpected ability of this knockdown to 
decrease  Puma  expression.  The  mechanism  involved,  which 
was also detected in Bax-deficient cells, remains to be charac-
terized. It should also be noted that knockdown of Bcl-xL in 
control cells provoked the apparition of a truncated form of Bax 
of an apparent molecular mass of 18 kD. This may be a conse-
quence of the induction of cell death, as this truncation, which 
has been reported in many cases of apoptosis induction and re-
sults in the removal of Bax H1 from the rest of the molecule 
(Cartron  et  al.,  2004b),  was  not  observed  in  Puma-deficient 
cells. In all cases, the view that emerges from these assays is 
that Bcl-xL acts in an ABT-737–sensitive manner to counteract 
a constitutive Puma-related death signal.
Puma mediates apoptosis induced by 
pharmacological inhibition of Bcl-xL 
combined with Mcl-1 down-regulation
ABT-737 does not inhibit Mcl-1 (Oltersdorf et al., 2005), and 
Puma does interact with this survival protein (Chen et al., 2005). 
Thus, the involvement of Puma in the aforementioned deleteri-
ous effects of ABT-737 may rely on the ability of this protein to 
counteract Mcl-1 rather than on its ability to activate Bax di-
rectly. We analyzed whether Puma was still involved in the in-
duction of death by ABT-737 in cells devoid of Mcl-1. Because 
we were unable to produce a lentivirus construct that would sig-
nificantly knock down Mcl-1 in HCT116 cells, we used a previ-
ously published procedure in which siRNAs targeting Mcl-1 
were transiently transfected (Fig. 6 A; Maiuri et al., 2007). Mcl-1 
knockdown by transfection of siRNAs induced only a modest 
increase in the amount of cells with released cytochrome c and 
active caspase 3 by itself (Fig. 6 B), but it allowed a more effi-
cient induction of these apoptotic events by a 24-h treatment 
with 1 µM ABT-737 in control cells. In contrast, Puma
/ cells 
were not sensitized to ABT-737–induced cell death by Mcl-1 
knockdown,  and  remained  significantly  more  resistant  to 
ABT-737–induced cell death under these conditions (Fig. 6 B). 
Thus, Puma still exerts proapoptotic activity when Mcl-1 is 
down-regulated and Bcl-xL is inhibited.
Conversely, we analyzed whether increased expression of 
Mcl-1 would protect cells from ABT-737–induced cell death 
and whether this would be Puma dependent. Flag-tagged Mcl-1 
was transiently transfected in control and Puma
/ cells, cells 
were treated with a high concentration of ABT-737, and the per-
centage of Flag-positive cells exhibiting active caspase 3 was 
evaluated by immunocytochemistry. Although, in a Puma-
proficient context, the percentage of cells displaying caspase 3 
activation after ABT-737 treatment was lower in the Flag–
Mcl-1–expressing population than in the mock-transfected one, 
this was not the case in a Puma-deficient background (Fig. 6 C). 
This puts forth the notion that Mcl-1 regulates ABT-737–induced 
Figure 5.  Role of endogenous Puma in the induction of apoptotic cell 
death  by  down-regulation  of  Bcl-xL  in  human  cancer  colorectal  cells.  
(A) Expression of Bcl-2 family members in HCT116-derived cell lines after 
down-regulation of Bcl-xL. Western blot (WB) analysis of Puma, Bax, Bcl-xL, 
and Mcl-1 in lysates from the indicated cells was performed 3 d after 
infection with the indicated recombinant lentivirus. The asterisk indicates 
a truncated form of Bax of 18 kD. (B) Induction of cell death by down-
regulation of Bcl-xL in human colorectal cancer cells. The indicated cells 
were infected with the indicated lentivirus, and induction of cell death was 
assayed by a trypan blue–staining procedure 3 d later. (C) Activation of 
caspase 3 by down-regulation of Bcl-xL in human colorectal cancer cells.   
The indicated cells were infected with the indicated recombinant lenti-
virus, and activation of caspase 3 was evaluated as described in Fig. 4 B 
2 d later. (B and C) Data are mean ± SEM of three independent experi-
ments. P-values were assessed using paired Student’s t tests. ShRNA, short 
hairpin RNA.JCB • VOLUME 185 • NUMBER 2 • 2009   286
proteins to interact substantially. Collectively, these assays sug-
gest that the BH3-binding activity of Bcl-xL maintains survival 
by preventing Puma and Bax to interact with each other. Because 
some interaction was detected between Puma and Bax in viable 
cells, Bcl-xL may also protect cells from the consequence of 
these interactions.
Discussion
Although it has been proposed that Bax activation may be initi-
ated by a subgroup of BH3 domains, so far, it has remained un-
clear whether the BH3 domain of Puma classifies as an activator. 
Analysis of Bax activation by truncated Bid in model assays has 
put forth the notion that Bax activation is a stepwise mechanism 
that relies on a series of reversible binding interactions with dif-
ferent rates initiated by transient events (Lovell et al., 2008). 
Thus, an initiating interaction between Bax and an activating 
BH3 domain may be elusive because of its fugacious nature and 
because of its potent inhibition by BH3-binding Bcl-2 homo-
logues, which maintain cell survival. Thus, our analysis of a 
physical and functional interaction between Puma and Bax was 
focused on the definition of molecular motifs involved in this 
interaction and on the investigation of its consequences in cellular 
contexts in which Bcl-2 homologues are absent and/or inhibited.
We recently found that Puma could interact with the first 
 helix of Bax and then showed that Puma or its BH3 domain 
Pharmacological inhibition of Bcl-xL 
enhances interactions between endogenous 
Puma and Bax
The aforementioned experiments show that the ability of Puma 
to mediate cell death induced by ABT-737–mediated Bcl-xL in-
hibition is independent from Mcl-1. They favor the notion that a 
direct interaction between Puma and Bax would be involved in 
this cell death process. We analyzed the effects of ABT-737 on 
intermolecular interactions between endogenous Bcl-xL, Bax, 
and Puma by coimmunoprecipitation experiments using lysates 
from cells treated with 1 µM ABT-737, which is an experimental 
condition that does not trigger major cell death (Fig. 4). As shown 
in Fig. 7 A, such treatment almost completely abolished the inter-
actions between Bcl-xL and Bax in control cells. This was also 
the case in Puma
/ cells (Fig. 7 C). This indicates that inhibition 
of Bax–Bcl-xL interactions is not an indirect consequence of cell 
death induction. It implies that the role of Puma in ABT-737 acti-
vity is not to allow this compound to disrupt Bax–Bcl-xL com-
plexes and, conversely, that disruption of Bax–Bcl-xL complexes 
that preexist in Puma
/ cells is insufficient to promote full-
blown apoptosis. In control cells, ABT-737 also disrupted the 
interactions between Puma and Bcl-xL (Fig. 7 A). Most notably, 
coimmunoprecipitation showed that some interaction between 
Puma and Bax occurred in untreated cells and that it was en-
hanced by ABT-737 treatment (Fig. 7 B). Thus, ABT-737 treat-
ment frees both Bax and Puma from Bcl-xL and allows these two 
Figure 6.  Role of Mcl-1 in Puma-dependent apoptosis induced by ABT-737. (A and B) Down-regulation of Mcl-1. The indicated cells were transfected with 
the indicated siRNA. 48 h later, Western blot analysis of Mcl-1, Puma, Bax, and Bcl-xL (A) and treatment with 1 µM ABT-737 (B) were performed. Induction 
of cytochrome c release and caspase 3 activation were analyzed as described for Fig. 4 B. NT, not treated. (C) Overexpression of Mcl-1. The indicated 
cells were transfected with the indicated plasmid. 24 h later, cells were treated with 10 µM ABT-737 for an additional 24 h. Immunocytochemical analysis 
of active caspase 3 and of Flag expression was then performed. For Flag–Mcl-1–transfected cells, the percentage of Flag-positive cells that also stained 
positive for active caspase 3 was evaluated. For mock-transfected cells, the percentage of cells that stained positive for active caspase 3 was evaluated in 
random populations. (B and C) Data are mean ± SEM of three independent experiments. P-values were assessed using a Student’s t test.287 BAX ACTIVATION BY PUMA • Gallenne et al.
be involved in its interaction with Puma BH3. The involvement 
of regions other than the BH3 domain of Puma in the interaction 
between Puma and Bax has also been suggested by a recent 
study (Yee and Vousden, 2008).
In the native conformation of Bax, Bax H1 is in the vicin-
ity of Bax H2, which contains the BH3 domain. Moreover, a 
salt bridge formed between D33 within the C-terminal end of 
Bax H1 and K64 within the BH3 domain participates in the 
maintenance of Bax in an inactive state (Cartron et al., 2005). 
Thus, it is tempting to speculate that an intermolecular inter-
action between Puma BH3 and Bax H1 might help to initiate an 
unfolding of the Bax molecule. This process, which could also 
play a role in Bax activation by Bim, as Bax H1 is also involved 
(Gavathiotis et al., 2008), might allow the complete activation of 
Bax to occur, possibly in combination with additional amplifica-
tory mechanisms (Lakhani et al., 2006; Zhu et al., 2006). It 
should be noted that Bax H1 might be involved in other 
protein–protein interactions engaged by Bax such as that with 
TOM22 (Bellot et al., 2007). Thus, Puma and Bax may end up in 
distinct protein complexes during the course of cell death. This 
aspect is reminiscent of what was reported for the Bid–Bax inter-
play (Grinberg et al., 2005).
Yeast cells, which express no recognized Bcl-2 family 
proteins, tolerate the heterologous expression of wild-type, 
untagged Bax but undergo mitochondrial permeabilization and 
cell death when expressing constitutively active variants of Bax 
(Arokium et al., 2004). Thus, the fact that, in this paradigm, 
could promote Bax interaction with mitochondria in cell-free 
assays and trigger its proapoptotic activity (Cartron et al., 2004a). 
The evidence provided in this study suggests that the latter ef-
fect involves, at least in part, a physical interaction between the 
BH3 domain of Puma and Bax, as the enhancement of Bax 
activity by Puma
BH3 is prevented by a minimal peptide that pre-
vents this physical interaction. This peptide was designed from 
a Pepscan analysis, which further substantiated our previous de-
scription of an interaction between Bax H1 and Puma BH3 
(Cartron et al., 2004a) and underscored the role of the C-terminal 
end of Bax H1 in this interaction. Our analysis also hinted to a 
possible interaction between Puma
BH3 and Bax H4, which is 
close to the Bax BH1 domain that was initially suggested to 
play a role in an interaction with Bid (Wang et al., 1996). How-
ever, a 7-mer peptide comprising residues 92–98 (within Bax 
H4) proved insufficient to prevent Puma BH3–Bax interactions 
in pull-down assays (unpublished data). The roles of other re-
gions within Bax in its interaction with Puma also require fur-
ther elucidation. In particular, a recent study published after 
submission of this manuscript shows that not only residues in 
Bax H1 but also residues in Bax H6 might be critically involved 
in ligand-induced activation of Bax by a stabilized Bim BH3 
peptide (Gavathiotis et al., 2008). In our study, because Pepscan 
analysis using biotinylated Puma BH3 and peptides covering 
the sequence of Bax between residue 107 and residue 194 did 
not yield any significant result (unpublished data), we currently 
do not know whether, or which, additional regions in Bax might 
Figure 7.  Effect of ABT-737 on intermolecular 
interactions involving Bax, Bcl-xL, and Puma. 
(A)  Interactions  between  Bcl-xL  and  Bax  or 
Puma. HCT116 p21
/ cells were treated or 
not treated () with 1 µM ABT-737 for 24 h. 
Cell lysates were immunoprecipitated (IP) with   
an anti–Bcl-xL antibody as described in Ma-
terials and methods, and the presence of Bcl-xL,   
Bax,  and  Puma  in  the  immunoprecipitated 
fractions  was  analyzed  by  immunoblotting. 
The amount of Bax and Puma that were co-
immunoprecipitated with Bcl-xL in each condi-
tion was evaluated by densitometric analysis 
and normalized to the amount of protein that 
coimmunoprecipitated with Bcl-xL in untreated 
cells. (B) Interactions between Puma and Bax. 
Experiments were performed as in A using an 
anti-Bax  antibody  for  immunoprecipitation. 
The amount of Puma that was coimmunopre-
cipitated with Bax in each condition (evaluated 
by densitometric analysis) was normalized to 
the amount of protein that coimmunoprecipi-
tated with Bax in treated cells. (C) Interactions 
between  Bcl-xL  and  Bax  in  Puma  knockout 
cells.  Experiments  were  performed  as  in  A 
using  HCT116  p21
/Puma
/  cells.  (A–C) 
Data are mean ± SEM of three independent 
experiments. P-values were assessed using a 
Student’s t test. WB, Western blot.JCB • VOLUME 185 • NUMBER 2 • 2009   288
Importantly, low levels of Puma appear sufficient to prime 
cells to death and lock them in a Bcl-xL–dependent state. Thus, 
when Puma expression is increased, it is possible that its accu-
mulation in complexes with Bcl-xL (and thus the ability of ad-
ditional Puma molecules to interact with Bcl-xL) may play a 
significant role in Puma-dependent cell death (Chipuk et al., 
2005; Ming et al., 2006; Yee and Vousden, 2008). Another im-
plication is that Puma may exert a proapoptotic function that 
will be lost only when its expression is completely abrogated. 
This may explain differences found between experiments that, 
albeit performed similarly, used Puma knockout versus Puma 
knockdown cells (Kim et al., 2006; Willis et al., 2007). It is also 
noteworthy that Puma knockout HCT116 cells still show some 
response to ABT-737. Thus, Puma expression may not be an 
absolute requirement for induction of cell death by Bcl-xL 
inhibition. Along this line, it is important to note that we have 
shown that survival antagonist BH3 domains could promote the 
release of active Bax from Bcl-xL by themselves, implying that 
sensitizer  molecules  can  launch  a  Bax-dependent  apoptotic 
program without additional Bax-activating signals (Moreau 
et al., 2003; Cartron et al., 2005). The ability of ABT-737 to 
displace Bax from Bcl-xL in Puma-deficient cells may account 
for the small rates of Bax-dependent cell death we observed in 
these cells.
With increasing evidence of secondary effects and possi-
ble acquisition of resistance to ABT-737, predictive markers of 
sensitivity and resistance to this compound are crucial. Puma 
expression can be driven downstream of diverse tumor suppres-
sor and/or oncogenic pathways because Puma is a direct tran-
scription target of p53, p73, Foxo3A, and E2F-1 (Nakano and 
Vousden, 2001; Yu et al., 2001; Hershko and Ginsberg, 2004; 
Melino et al., 2004; You et al., 2006). Our results suggest that 
these pathways might install some sensitivity to wide-range or 
selective inhibitors of Bcl-2 homologues in cancer cells. Con-
versely, posttranslational mechanisms that negatively regulate 
Puma activity and allow cells to accumulate this protein without 
undergoing cell death are expected to promote resistance against 
such inhibitors.
Materials and methods
Cell culture and cell lines
BdGBM  and  BeGBM  cells  were  described  previously  (Cartron  et  al., 
2003). BdGBM(Bax-), BdGBM(BaxD33A), and BdGBM(BaxK64A) cells 
were described previously (Cartron et al., 2004a). GBM shBax and GBM 
scr cells were also described previously (Manero et al., 2006). Human 
colorectal cancer cells lines derived from HCT116 (p21
/, p21
/ 
Puma
/, and p21
/Bax
/) were provided by B. Vogelstein (The John 
Hopkins Kimmel Cancer Center, Baltimore, MD; Yu et al., 2003). GBM 
samples were provided by S. Martin (Hôpital G et R Laennec, Centre Hos-
pitalier  Universitaire,  Nantes,  France)  and  M.  Campone  (Centre  René 
Gauducheau, Nantes-Atlantique, Nantes, France).
Antibodies
Anti–Bcl-xL (for immunoprecipitation [Epitomics] and for Western blotting 
[Transduction Laboratory]), anti–Bax 2D2 (for immunoprecipitation [Sigma-
Aldrich] and for Western blotting [Dako]), anti–cytochrome c (R&D Sys-
tems), anti–active caspase 3 (BD), anti-Puma (Sigma-Aldrich), anti–Mcl-1 
(Tebu-bio), antiactin (Millipore), and anti-Flag (Sigma-Aldrich) were used. 
Horseradish peroxidase–conjugated antibodies and enhanced chemilumines-
cence reagents were obtained from Santa Cruz Biotechnology, Inc. Fluorescent 
secondary antibodies were obtained from Invitrogen.
Puma physically interacts with Bax and switches on its killing 
activity by a Bax H1–, Bcl-xL–sensitive process strongly 
underscores the potency of Puma to initiate Bax activation by 
itself. The ability of Puma to activate Bax in yeast is reminis-
cent of a similar effect recently reported for the short form of 
Bim (Weber et al., 2007). This work implies that the interaction 
of Bim with mitochondria is critical and that mechanisms other 
than protein–protein interactions could be at stake. Bax-activating 
signals can be provided by nonfamily proteins or nonprotein-
aceous factors (Kuwana et al., 2002; Lalier et al., 2007b). 
Therefore, it is possible that Puma may have an impact on such 
mechanisms, having an effect that, added to its ability to inter-
act with Bax, will lead to efficient cell death. As we observed 
that, in yeast cells, Puma is essentially cytosolic (unpublished 
data), such additional signals would rely on different molecular 
mechanisms than those proposed for Bim (Weber et al., 2007). 
Because expression of cytosolic Puma leads to an accumulation 
of Bax at the mitochondria in yeast (unpublished data), the yeast 
system argues for a “touch and go” type of interaction between 
Puma and Bax.
A genuine activator BH3-only protein is expected to play 
an active role when mammalian cell death is induced by inhibi-
tion of Bcl-2 homologues. Along this line, it is important to note 
that  endogenous  Puma  is  involved  in  efficient  induction  of 
apoptosis in HCT116 cells by the small compound ABT-737. 
Although other death agonist BH3-only proteins might be me-
diators of ABT-737–induced cell death in certain cell systems 
(most notably Bim; Del Gaizo Moore et al., 2007), knockdown 
of Bim and Bid expression in HCT116 cells had no detectable 
impact on ABT-737–induced cell death (Fig. S4 A), implying 
that Puma’s role in this case is not upstream of these proteins. 
Likewise, down-regulation of Bak had no detectable effect on 
ABT-737 induction of cell death in the same cells (Fig. S4 B), 
suggesting that this protein is also dispensable for this process 
and underlining the major role played by the Puma–Bax axis. 
Most importantly, Puma is involved in ABT-737–induced cell 
death even in conditions under which Mcl-1 expression is down-
regulated, and, on a molecular level, ABT-737 treatment en-
hances Bax–Puma interactions at the same time as it prevents 
the interaction of each of these proteins with Bcl-xL. These ob-
servations support the notion that Puma is a death agonist BH3-
only protein that, as such, provides a tonic death signal that the 
combined  BH3-binding  activities  of  Bcl-2  homologues  will 
have to continuously counterbalance to maintain survival.
This notion is best exemplified by our observation that 
although Puma or Bax knockout cells tolerate Bcl-xL down-
regulation, control HCT116 cells undergo massive cell death after 
such down-regulation. Compared with Bcl-xL down-regulation, 
Bcl-2 down-regulation (unpublished data) and Mcl-1 down-
regulation (at the very least in the experimental conditions used) 
only had a modest effect on the viability of HCT116 cells. This 
indicates that Bcl-xL is more critically involved in maintain-
ing the survival of these cells than its homologues. The reason 
for this apparent selectivity is unclear, but, strikingly, it re-
calls a previous study that showed that Bcl-xL much more   
potently prevents Puma function than Bcl-2 or Mcl-1 (Ming   
et al., 2006).289 BAX ACTIVATION BY PUMA • Gallenne et al.
protein lysates in CHAPS buffer, were performed with the IP-50 immuno-
precipitation kit according to manufacturer’s recommendations. For long-term 
assays, 500 cells were seeded in each well of a 6-well plate 24 h before 
the start of a 2-wk continuous treatment, after which cells were stained with 
0.5% crystal violet and 20% methanol.
Online supplemental material
Fig. S1 shows physical and functional interactions of Bax with BH3 peptides. 
Fig. S2 shows the impact of H1-Cter on Puma induction of apoptosis. Fig. S3 
shows additional data regarding the role of Puma in ABT-737 induction of cell 
death. Fig. S4 shows the lack of contribution of Bid, Bim, and Bak in ABT-737 
induction of cell death in HCT116 cells. Table S1 shows sequences of pep-
tides and of Puma cDNA used in this study. Online supplemental material is 
available at http://www.jcb.org/cgi/content/full/jcb.200809153/DC1.
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Peptides, recombinant proteins, and peptide scan
Peptides (Table S1) were obtained from Sigma-Aldrich and NeoMPS Poly-
peptide Laboratories. Small-scale preparation of recombinant His-Bax from 
bacterial lysates was performed as described previously (Cartron et al., 
2002). Peptide scanning was performed as previously described using 
nitrocellulose membranes on which 12-mer peptides covering the indicated 
sequence of Bax were spotted (Bellot et al., 2007). 1 µg/ml biotinylated 
Puma
BH3 was incubated with membranes overnight at 4°C and, after three 
washes with PBS and 1% BSA, was detected using extravidin-coupled 
horseradish peroxidase. Binding intensities were quantified using IP Labo-
ratory Gel software (Signal Analytics).
Yeast assays
Yeast-expressing  galactose-inducible  Bax  (or  BaxD33A),  Bcl-xL,  and/or 
Puma was obtained by transforming the wild-type haploid strain W303-1B 
(Mata, ade2, his3, leu2, trp1, and ura3) with expression vectors express-
ing the corresponding cDNA under control of the GAL1/10 promoter and 
expressing URA3, HIS3, and TRP1 as yeast selection markers, respectively 
(Arokium et al., 2004). A chimeric Puma cDNA optimized for expression 
(Genescript) was used (Table S1). Survival after the addition of 0.5% 
galactose to cultures in early exponential growth phase was evaluated by 
plating 250 cells on complete medium and counting formed colonies 48 h 
later. Cytochrome c release was measured by redox spectrometry on iso-
lated mitochondria as previously described using cytochrome b as an inter-
nal  standard  (Arokium  et  al.,  2004).  Immunoprecipitation  experiments 
were performed with the IP-50 immunoprecipitation kit (Sigma-Aldrich) ac-
cording to the manufacturer’s instructions, using 2 µg of antibody and 2–5 mg 
of protein from zymolyase-treated whole cell lysates in 500 µl IP-50 buffer 
(Sigma-Aldrich).
Pull-down assays
1 µM biotinylated Puma
BH3 was incubated with 500 µg of GBM cell extract 
in 500 µl of CHAPS buffer (10 mM Hepes, 150 mM NaCl, 1% CHAPS, 
pH 7.4, and EDTA-free protease inhibitors cocktail) with or without the 
competing peptide for 2 h under agitation at 4°C. 30 µl of avidin–agarose 
beads, previously washed twice with CHAPS buffer, were then added and 
incubated overnight under agitation at 4°C. After three washes in 500 µl 
of CHAPS buffer, beads were resuspended in 30 µl of 2× Laemmli buffer 
and boiled for 30 s at 95°C before Western blotting.
RNA interference and transfection assays
Lentivirus production and titration were performed as described previously 
(Qin et al., 2003) using HEK293-FT as packaging cells and FG12 lenti-
vector in which an scr negative control (Applied Biosystems) or short hairpin 
RNA targeted to oligonucleotides 58–76 of human Bcl-xL under the control 
of the U6 promoter were subcloned. A multiplicity of infection of 4 was 
used. Mcl-1 and control siRNA were purchased from Applied Biosystems. 
Cells were transfected using the HiPerfect transfection reagent (QIAGEN) 
according to the manufacturer’s instructions and were incubated with 
nucleotides for 48 h before subsequent experiments. Transfection with plas-
mids was performed using Lipofectamine 2000 reagent (Sigma-Aldrich) 
according to the manufacturer’s instructions.
Cellular assays
Cytoplasmic microinjection and morphological analysis of cell death in fluor-
escent cells were described previously (Cartron et al., 2004a). For immuno-
cytochemical  assays,  cells  were  washed  with  PBS  and  fixed  with  4% 
paraformaldehyde and 0.15% picric acid in PBS for 30 min at RT. Cells 
were washed three times in PBS and permeabilized with 0.1% SDS in PBS 
for 10 min at RT. Cells were washed again and, after a 30-min saturation 
with 5% gelatin in PBS at 37°C, were incubated with primary antibodies 
diluted in 1% gelatin in PBS for 1.5 h at 37°C. After three washes in PBS, 
incubation with secondary antibodies (anti–mouse IgG coupled to Alexa 
Fluor 488 and anti–rabbit IgG coupled to Alexa Fluor 568) was performed 
in 1% gelatin in PBS for 1.5 h at 37°C. Cells were then washed and 
mounted in ProLong Gold antifade reagent (Invitrogen). Cells that had not 
been infected with lentivirus were inspected at RT with a fluorescent micro-
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